Ron DePinho, Professor of Department of Cancer Biology, Division of Discovery Science at MD Anderson Cancer Center, shared on LinkedIn:
“An important advance in understanding and therapeutically exploiting cancer cell plasticity in colorectal cancer — a major cancer killer.
This study identifies TROP2 as a marker of aggressive, WNT-low, fetal-like tumor cells with metastatic capacity and resistance to therapy. Conventional chemotherapy enriches these TROP2-positive states, whereas TROP2-directed antibody–drug conjugates selectively eliminate them and reshape the tumor cell-state landscape.
The therapeutic implication is compelling: chemotherapy and TROP2 targeting attack complementary tumor states, producing greater efficacy in patient-derived models. Cancer cells do not remain fixed during treatment. Mapping how therapy changes cell state and targeting the resistant states it creates may be essential to controlling metastatic disease.”
Title: TROP2 targeting reveals therapy-driven cell state dynamics in colorectal cancer
Authors: Nuria Vaquero-Siguero, Nikolaos Georgakopoulos, Maria C. Puschhof, Ioannis Chiotakakos, Jasmin Meier, Sigrid K. Fey, Gabriele Diamante, Manuel Mastel, Aitana Guiseris-Martinez, Guillaume Belthier, Nikolai Schleußner, Julia Volk, Carolin Artmann, Bryce Lim, Ronald Koschny, Cyrill Wehling, Kyanna S. Ouyang, Michael Günther, Solveig Kuss, Paula Hoffmeister, Moritz Mall, Jens Neumann, Steffen Ormanns, Martin Schneider, Thomas Schmidt, Jens Puschhof, Andreas Trumpp, Jacco van Rheenen, Julio Saez-Rodriguez, Bruno C. Köhler, Rene Jackstadt
Read the Full Article on Nature.
Other posts featuring Ron DePinho on OncoDaily.